Sickle cell disease

Research output: Contribution to journalArticlepeer-review


Sickle cell disease is an umbrella term for a group of hemoglobinopathies characterized by the presence of 2 β-globin gene mutations or deletions, at least 1 of which is the point mutation that leads to the production of hemoglobin S. Sickle cell disease is associated with hemolytic anemia, significant chronic end-organ damage, and early death. In high-income countries, at least 95% of children with the disease survive into adulthood, resulting in a growing population of affected adults with significant comorbidities, complex medical issues, and not enough specialists to provide care. Hydroxyurea is the primary therapy, and recent advances in understanding disease pathophysiology have led to new therapies; progress in bone marrow transplant and gene editing has resulted in cure in some patients. The purpose of this review is to provide an overview of the diagnosis, common acute and chronic clinical manifestations, and best practices for management of sickle cell disease.

Original languageEnglish (US)
Pages (from-to)ITC1-ITC16
JournalAnnals of internal medicine
Issue number1
StatePublished - Jan 1 2021

ASJC Scopus subject areas

  • Internal Medicine


Dive into the research topics of 'Sickle cell disease'. Together they form a unique fingerprint.

Cite this